Work

Incremental Diagnostic Value of Serum Tumor Markers Beyond Multimodal Ultrasound for BI ‐ RADS Category 4 Breast Lesions: A Retrospective Diagnostic Modeling Study

Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVES: To determine the incremental diagnostic value and potential clinical utility of serum tumor markers beyond multimodal ultrasound for differentiating benign from malignant Breast Imaging Reporting and Data System category 4 breast lesions. METHODS: This retrospective diagnostic modeling study included 307 patients with 1 pathologically verified BI-RADS category 4 lesion each. Three nested logistic regression models were evaluated: BI-RADS subcategory alone, multimodal ultrasound comprising clinical and ultrasound variables, and multimodal ultrasound plus normalized serum CA15-3, CEA, CA125, and CYFRA21-1 ratios. Discrimination, calibration, Brier score, integrated discrimination improvement, likelihood-ratio testing, bootstrap internal validation, and decision-curve analysis were assessed. Prespecified analyses evaluated lesions 20 mm or smaller and patients with all 4 markers within reference limits. RESULTS: Of 307 lesions, 184 (59.9%) were malignant. The area under the receiver operating characteristic curve increased from 0.875 (95% CI, 0.837-0.913) for BI-RADS alone to 0.920 (95% CI, 0.888-0.952) for multimodal ultrasound and 0.953 (95% CI, 0.931-0.976) after addition of serum markers. Relative to multimodal ultrasound, the combined model improved the AUC by 0.033 (95% CI, 0.013-0.055; p = .002), reduced the Brier score by 0.025 (95% CI, 0.011-0.040; p < .001), and yielded an integrated discrimination improvement of 0.103 (95% CI, 0.069-0.138; p < .001). Bootstrap-corrected AUCs were 0.908 and 0.940, respectively. In lesions 20 mm or smaller, AUC increased from 0.934 to 0.970 (p = .003). In the all-marker-negative subgroup, the corresponding increase from 0.912 to 0.930 was not statistically significant (p = .229), although cohort-derived combined-model tertiles showed malignancy rates of 4.0, 24.5, and 89.8% (p for trend <.001). CONCLUSIONS: Serum tumor markers provided statistically significant incremental information beyond multimodal ultrasound in this BI-RADS category 4 cohort, with a particularly clear improvement among small lesions. The marker-negative risk-stratification findings are exploratory. External validation and prospective assessment of clinical pathways are required before implementation.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W7234414260
FWCI:
Cites: 23
Cited by:
Related to: 10